Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings
By Dan Moskowitz January 15, 2013
With shares of Forest Laboratories is FRX an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our ,Forest Laboratories failed to meet expectations. This would often mean a good reason to sell. However, in some cases, it presents a buying opportunity. Is this one of those cases? Let’s take a look......
As stated earlier, the long-term story for Forest Laboratories is likely a good one. If you’re ever concerned, just take a look at the balance sheet. It can act as a reminder that there is plenty of time and money for more drugs in the pipeline. Losing exclusivity on Lexapro was a big hit, but that has now been priced into the stock price.
Forest Laboratories is far from a one-trick pony like so many companies in this industry. There will be disappointments, and there will be home runs. In the end, the good will outweigh the bad.
As long as the market stays afloat, Forest Laboratories is a long-term OUTPERFORM.